TLDR: The sale is heavily financed with new debt making bankruptcy a possibility. Selling off pieces of the company and closing stores is most likely to happen.
Who at Sycamore Partners Will Run Walgreens?
Stefan Kaluzny, Managing Director of Sycamore Partners, has been prominently mentioned in connection with the acquisition. He expressed confidence in WBA’s pharmacy-led model and its role in healthcare, suggesting he may play a strategic oversight role rather than day-to-day management.
John A. Lederer, a Senior Advisor to Sycamore Partners since 2017, is a key figure with relevant experience. Lederer has a strong background in retail and pharmacy operations, having served as Chairman and CEO of Duane Reade (acquired by Walgreens in 2010) and as President of Loblaw Companies, Canada’s largest grocery retailer. He also served as Executive Chairman of Staples, a Sycamore portfolio company. Given his experience, Lederer could play a significant role in guiding Walgreens’ operational or strategic direction, though there’s no confirmation he will directly “run” the company.
Sycamore Partners typically operates as a private equity firm that provides strategic oversight and financial restructuring rather than installing its own executives to manage daily operations. They are likely to work with existing Walgreens leadership, potentially supplemented by advisors like Lederer, to execute their vision.
Likely Changes at Walgreens Based on Sycamore’s History
Sycamore Partners specializes in retail, consumer, and distribution-related investments, with a track record of acquiring distressed or undervalued companies and implementing aggressive turnaround strategies. Based on their history and the current state of Walgreens, the following changes are likely:
Store Closures and Asset Sales:
Sycamore’s Track Record: Sycamore has a history of acquiring struggling retailers (e.g., Staples, Belk, Talbots, Nine West) and often focuses on cost-cutting, including closing underperforming stores and selling off valuable assets. For example, Belk and Nine West filed for bankruptcy under Sycamore’s ownership, with significant store closures.
Walgreens Context: Walgreens has already announced plans to close 1,200 of its roughly 8,500 U.S. stores by 2027, with 500 closures planned for fiscal 2025. Sycamore is likely to accelerate or expand this strategy, targeting unprofitable locations (approximately up to 25% of Walgreens’ U.S. stores are unprofitable). Additionally, Sycamore is actively seeking to monetize Walgreens’ interests in VillageMD, Summit Health, and CityMD, potentially generating up to $3.4 billion, though some analysts estimate a lower value of around $1 billion.
Debt Restructuring and Financial Discipline:
Sycamore’s Approach: Sycamore’s acquisition of Walgreens is heavily debt-financed, with 83.4% of the $23.7 billion deal (approximately $18.3 billion) funded through debt, significantly higher than the 41% average for private equity deals in 2024. This leveraged buyout strategy often requires portfolio companies to prioritize debt servicing, which can constrain investments in innovation or workforce development.
Walgreens Context: Walgreens is already burdened with $9 billion in debt and faces opi--d-related liabilities. Sycamore may push for aggressive cash flow improvements, such as reducing operational costs, selling non-core assets, or restructuring existing debt. The company has already suspended its quarterly dividend and reduced its stake in Cencora to improve liquidity.
Potential Impact: The high debt load increases the risk of financial distress or bankruptcy, as noted by analysts. This could lead to further cost-cutting measures, potentially affecting employee wages, benefits, or job security.
Focus on Retail Optimization:
Sycamore’s Expertise: Sycamore has a strong track record in retail turnarounds, leveraging operational improvements to boost profitability. For example, at Staples, Sycamore optimized store operations and introduced new private-label products.
Walgreens Context: Walgreens’ retail business (“front-of-store” sales) has been neglected, contributing to $27 billion in non-pharmacy revenue but with declining margins due to competition from Amazon, Walmart, and others. Sycamore is likely to focus on enhancing the retail experience, such as expanding private-label products (Walgreens has already introduced 300 new store-brand products) and improving store layouts or delivery services.
Potential Impact: Investments in retail could improve customer retention and margins, but Sycamore’s lack of healthcare experience may limit their ability to address pharmacy-specific challenges, such as low reimbursement rates.
Staff and Operational Changes:
Sycamore’s History: Sycamore’s portfolio companies, such as Staples, have faced criticism for labor practices, including serious OSHA violations and a lack of union presence. The Private Equity Stakeholder Project (PESP) gave Sycamore a failing labor scorecard (51.73%). Cost-cutting often involves reducing staff hours or layoffs, as seen in other Sycamore acquisitions.
Walgreens Context: Walgreens employs approximately 312,000 people globally. Staff hour reductions have already strained customer service, as noted in Reddit discussions, and Sycamore’s cost-cutting approach could exacerbate this. Analysts have expressed concerns about potential layoffs, with one estimating “tens of thousands” of job losses to manage debt.
Potential Impact: Reduced staffing or hours could further degrade customer service, risking customer loss, especially in pharmacy services where trust and accessibility are critical.
Potential Breakup of the Company:
Sycamore’s Strategy: The Wall Street Journal reported that Sycamore may consider breaking up Walgreens, selling off parts of the business to maximize value. This aligns with their past strategy of selling valuable assets from portfolio companies.
Walgreens Context: Walgreens’ portfolio includes U.S. retail pharmacies, international operations (Boots in the UK, Benavides in Latin America), and health services like VillageMD. Sycamore may explore selling international assets or non-core businesses to reduce debt or focus on the U.S. pharmacy chain.
Potential Impact: A breakup could streamline operations but risks disrupting Walgreens’ integrated healthcare model and further reducing its market presence.
Long-Term Turnaround Focus:
Sycamore’s Approach: As a private company, Walgreens will face less pressure to meet quarterly earnings targets, allowing Sycamore to implement long-term strategies without public market scrutiny. This could enable investments in technology, store remodels, or new service models.
Risks and Concerns
Bankruptcy Risk: Analysts, including those from the Private Equity Stakeholder Project, warn that the high debt load increases Walgreens’ risk of bankruptcy, similar to Sycamore’s portfolio companies like Belk and Nine West. This could lead to significant job losses and reduced pharmacy access.
Healthcare Expertise Gap: Sycamore’s lack of experience in healthcare raises concerns about their ability to address pharmacy-specific challenges, such as declining reimbursement rates or regulatory complexities.